


CHIRON



Chiron Corporation
4560 Horton Street
Emeryville, California 94608-2916
510.655.8730
Corporate Fax 510.654.5360
Litigation Fax 510.923.2429
Intellectual Property Fax 510.655.3542

Law Department

August 18, 2003

BioMedicines, Inc.
2000 Powell Street, Suite 1640
Emeryville, CA 94608

Attn: Curtis Scribner, MD
Vice President Regulatory Affairs

Gentlemen:

This letter shall modify the Asset Purchase Agreement by and between BioMedicines, Inc. ("BMI") and Matrix Pharmaceutical, Inc. ("Matrix") dated November 7, 2002 (the "Purchase Agreement") and the Patent Assignment Agreement by and between BMI and Matrix dated November 7, 2002 (the "Patent Assignment"), to correct a reference to a certain patent application identified in the Purchase Agreement and the Patent Assignment as set forth below. Chiron Corporation ("Chiron") is the successor in interest to Matrix upon its dissolution on January 22, 2003.

Schedule 2.1(a) of the Purchase Agreement is modified by deleting the reference to the application bearing Chiron Series "19329", Name/Number(s) "Oxidized Collagen Formulations for Use with Non Compatible Pharmaceutical Agents" and Date Issued or Filed "US - 05/15/02", in each place where it appears and replacing each such reference with the application bearing Chiron Series "19329", Name/Number(s) "Oxidized Collagen Formulations for Use with Non Compatible Pharmaceutical Agents" and Date Issued or Filed "US - 05/15/01".


Schedule 1 of the Patent Assignment is modified by deleting the reference to the application bearing Chiron Series "19329", Name/Number(s) "Oxidized Collagen Formulations for Use with Non Compatible Pharmaceutical Agents" and Date Issued or Filed "US - 05/15/02", in each place where it appears and replacing each such reference with the application bearing Chiron Series "19329", Name/Number(s) "Oxidized Collagen Formulations for Use with Non Compatible Pharmaceutical Agents" and Date Issued or Filed "US - 05/15/01".

The incorrect filing date was inadvertently assigned to the application bearing the referenced Chiron Series number and title. This letter seeks to properly identify the transferred application, which bears U.S. Serial No. 09/858,247.


Please sign in the place where indicate below and return the original, retaining a copy for your files.

Very truly yours,

CHIRON CORPORATION

By: 
Title: William J. DeWitt, CEO

Acknowledged on behalf of BioMedicines, Inc.

By:  Date: 25 Aug 03
Title: V.P. REGULATORY AFFAIRS

1116609